Osaka-based biopharmaceutical startup AnGes, Inc. announced Monday that the government had accepted its registration for a clinical trial of a new coronavirus vaccine, which the startup developed jointly with Osaka University.
A trial to examine safety and effectiveness on humans is a prerequisite for government approval. AnGes plans to start the trial next Tuesday at the earliest, aiming for practical application in spring 2021 or later. It will become Japan's first case in which a clinical trial is conducted.
The Osaka prefectural and municipal governments are supporting development of the company's vaccine. In the trial, between 20 and 30 medical workers at Osaka City University Hospital will be vaccinated.
Read more from The Japan News at https://japannews.yomiuri.co.jp/
